首頁-形象圖03
Historical timeline
AUG 2018 Acquired Taiwan invention patent.
JUN 2018 Acquired Korean invention patent.
APR 2018 Acquired Russia invention patent.
NOV 2017 Acquired Australiainvention patent.
AUG 2017 Charsire was honored as 2017 Good Business Entity Issuing Uniform Invoices by the National Tax Administration of Southern Taiwan Province.
APR 2017 International certifications of ISO 9001:2015 (Manufacture of Skin Care Products) and ISO 22716 (Manufacture of Skin Care, Cosmetics, Toiletry and Hygiene Products).
APR 2017 The statistical analysis of the clinical results for our new drug relieving the head and neck cancer pain caused by RT, ACA, has been completed. The results showed that most subjects experienced no or mild pain throughout the study duration, and the dermatitis reaction of the radiation area was well-controlled which could be recovered after developing mild dermatitis. This suggested that ACA was able to keep the radiation patients continuously receiving radiation therapy and improve the effect of radiation treatment.
JAN 2017 Started patient enrollment in eight investigation centers over U.S. Phase 2 clinical trial investigating BAC in Alzheimer’s Disease or Vascular Dementia treatment.
AUG 2016 The new drug BAC for Alzheimer’s Disease or Vascular Dementia treatment was approved Phase 2 clinical trial by US FDA.
AUG 2016 ACA Phase 1 clinical trial recruitment finished.
MAY 2016 Charsire began the Industry-university cooperative project with National Taiwan Sport University. We expected to establish a new model for the collaboration between sports and industry and supplied our products for the cooperative research.
JAN 2016 Charsire pharmaceutical factory is recognized as PIC/S GMP Pilot Plant Facility.
APR 2015 Charsire was ranked in 2015 by Deloitte as one of the 500 fastest growing companies in Asia Pacific.
APR 2015 Charsire Charity Activities: Donate Clothing to Charity.
FEB 2015 The new drug ACA for relieving the head and neck cancer pain caused by RT was approved Phase 1 clinical trial by Taiwan FDA.
AGU 2014 The Phase 2 study for botanical new drug CSTC1 for Diabetic Foot Ulcers was granted by the Ministry of Economic Affairs.
APR 2014 The new drug CSTC1 for Diabetic Foot Ulcer was approved Phase 2 clinical trial by US FDA and Taiwan FDA and was allowed to start enrollment in KMUH, KMSH and KMTH.
APR 2014 Charsire CSTC1 diabetic wound healing new drug was approved to enter clinical trials.
SEP 2013 Charsire officially gained approval of public stock offering by Securities and Futures Bureau on 2013/8/26, and came into effect on 2013/9/12. Charsire stock symbols: 4196。 Charsire has been certified as model workplaces in Tainan city.。
JUL 2013 CSTC1 was approved by FDA  to enter phase II clinical trial.
JUN 2013 Obtain the pharmaceutical factory license on 2013/6/7.    Factory Certification : 94-B00105。
APR 2013 Officially certificated the patent for medical invention of skin care in Malaysia.
JAN 2013 According to banking rules of listed, OTC, and emerging stock companies and FSC, Charsire has started using IFRS financial statements to comply with international practice.
NOV 2012  Accomplish the research project of diabetes new drug, granted by Industrial Development Bureau.
MAY 2011 Accomplish the research issue, granted by Council of Agriculture, Executive Yuan
MAR 2011 Accomplish the research issue, High value product development of Legume and purple sweet potato, granted by Council of Agriculture, Executive Yuan.
FEB 2011 Accomplish the program, CSTC1 diabetes wound healing products of patent extracts, granted by Industrial Development Bureau.
2011 Honored as the company of phthalate test by Department of Health.
2010 Organized and set up Instrumentation Centers, in which contains HPLC, GC/MS/MS, LC/MS/MS, AA…etc.
DEC 2010 Introduce the first facial mask with plant extract, which is asepsis and preservative-free.
SEP 2010 International certifications of ISO 9001 (Manufacture of Skin Care Products) and 22716 (Manufacture of Skin Care, Cosmetics,Toiletry and Hygiene Products).
JUL 2010 Membership marketing of Sfons was established.
JUN 2009 Sfons Taipei branch office was established.
DEC 2008 The official opening of Charsire’s factory for R&D/ cosmetics in Tainan Science Park.
AUG 2008 The construction of Charsire’s factory in Tainan Science Park was started.
JUN 2008 Sfons Kaohsiung branch office was established.
APR 2008 Officially obtained European Patent Convention, including patents of Germany, France, England, Italy, and Netherlands.
OCT 2007 Officially certificated the second patent for medical invention of skin care in U.S. and  P.O.C.
SEP 2007 Invited to Bio Japan 2007 Exhibition.
FEB 2007 Officially certificated the patent for medical invention of skin care in E.U. and Singapore. The distribution channel of Sfons Biotech was established.
2007 Invited to Bio Japan 2007 Exhibition.
SEP 2006 Officially certificated the first patent for medical invention in U.S.
OCT 2005  Invited to Biotechnical 2005 in Hannover, Germany.
JUL 2005  Invited to Bio Taiwan 2005 Conferences & Exhibition.
JUL 2004 Invited to Bio Taiwan 2004 Conferences & Exhibition.
DEC 2003 Honor Award of Golden Peak award Outstanding Enterprise Manager Associates, R.O.C. Awarded the National Excellent Quality Product Golden Prize by the Consumers Association.
NOV 2003 Nomination of National Biotechnology Medicine Quality Award. Charsire Angastar officially came into the market.
OCT 2003 Approval of Ministry of Economics Affairs on capital of 600 million NTD.
AUG 2003 Apply for multinational patents in medicine. Patent pending countries: European Union (Britain, France, Germany, Holland, Greece, Italy, Spain , Portugal, Irish, Austria, Belgium,Sweden, Denmark, Finland, Luxembourg, Morocco, Switzerland, Turkey, Bulgaria, Estonia, Czech, Slovakia, Slovenia, Hungary ,Romania, .Liechtenstein, Cyprus), Canada, Australia, Japan, Korea, China, India, Malaysia,Singapore, Taiwan
FEB 2003 Officially approved by National Science Council as high biotechnology company of skin medical care and allowed establish and invest cGMP pharmaceutical factory in Tainan Science Park.
2001 preclinical function study of topical skin care with Kaohsiung Medical University